Search results for "Drug Interaction"

showing 10 items of 246 documents

Glycine receptors influence radial migration in the embryonic mouse neocortex.

2011

To investigate whether glycine receptors influence radial migration in the neocortex, we analyzed the effect of glycine and the glycinergic antagonist strychnine, on the distribution of 5-bromo-2'deoxyuridine-labeled neurons in organotypic slice cultures from embryonic mice cortices. Application of glycine impeded radial migration only in the presence of the glycine-transport blockers, ALX-5407 and ALX-1393. This effect was blocked by the specific glycine receptor antagonist strychnine, whereas application of strychnine in the absence of glycine was without effect. We conclude from these observations that an activation of glycine receptors can impede radial migration, but that the glycinerg…

GlycineCell CountNeocortexBiologychemistry.chemical_compoundMiceOrgan Culture TechniquesReceptors GlycineCell MovementGlial Fibrillary Acidic ProteinmedicineAnimalsDrug InteractionsReceptorGlycine receptorNeuronsNeocortexGeneral NeuroscienceAntagonistGlycine AgentsSarcosineGlycine receptor antagonistStrychnineStrychnineEmbryo MammalianCell biologymedicine.anatomical_structurechemistryBromodeoxyuridineCerebral cortexPhosphopyruvate HydrataseGlycineNeuroscienceNeuroreport
researchProduct

The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.

2000

The low immunogenic B16 melanoma cell line was transfected with a mammalian expression vector containing the complementary DNA for a sIL-6R/IL-6 fusion protein, termed Hyper-IL-6 (H-IL-6), which was shown to have biological activities at 100-1000-fold lower concentrations than IL-6 in combination with sIL-6R. The secreted p84 glycoprotein was detected in the supernatant of transfected cells and was fully active on BAF3/gp130 cells, which respond to IL-6/sIL-6R but not to IL-6 alone. Administration of recombinant H-IL-6 to C57BL/6 mice resulted in a prolonged acute phase protein gene expression indicating long systemic persistence of the fusion protein. Transfected B16 cells (B16/H-IL6 cells…

Graft RejectionCancer ResearchTumor suppressor geneRatónmedicine.medical_treatmentRecombinant Fusion ProteinsMelanoma ExperimentalMice TransgenicTransfectionchemistry.chemical_compoundMiceGene expressionGeneticsmedicineAnimalsDrug InteractionsInterleukin 6neoplasmsMolecular BiologybiologyInterleukin-6MelanomaGranulocyte-Macrophage Colony-Stimulating FactorReceptors Interleukinmedicine.diseaseReceptors Interleukin-6Growth Inhibitorsrespiratory tract diseasesCytokinechemistryCell cultureReceptors Granulocyte-Macrophage Colony-Stimulating FactorImmunologybiology.proteinCancer researchGrowth inhibitionImmunosuppressive AgentsOncogene
researchProduct

ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients

2017

International audience; The advent of safe and highly effective direct-acting antiviral agents (DAAs) has had huge implications for the hepatitis C virus (HCV) transplant field, and changed our management of both patients on the waiting list and those with HCV graft re-infection after liver transplantation (LT). When treating HCV infection before LT, HCV re-infection of the graft can be prevented in nearly all patients. In addition, some candidates show a remarkable clinical improvement and may be delisted. Alternatively, HCV infection can be treated post-LT either soon after the transplant, taking advantage of the removal of the infected native liver, or at the time of disease recurrence, …

Hepatitis C chronicDrugmedicine.medical_specialtyConsensusAntiviral agentmedicine.medical_treatmentHepatitis C virusmedia_common.quotation_subjectWaiting listDiseaseGuidelineLiver transplantationGuidelinesmedicine.disease_cause03 medical and health sciences0302 clinical medicineMED/12 - GASTROENTEROLOGIAMedicineHumansDrug InteractionsIntensive care medicinemedia_commonLiver transplant candidateLiver transplantationHepatologybusiness.industryWaiting listsLiver failure[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyRecurrent hepatitis CDirect Antiviral AgentHepatitis C3. Good healthSurgerychronicAntiviral agentsWaiting list030220 oncology & carcinogenesisInterferon030211 gastroenterology & hepatologyLiver transplant recipientInterferonsbusinessComplication
researchProduct

Effects of Anandamide and Noxious Heat on Intracellular Calcium Concentration in Nociceptive DRG Neurons of Rats

2007

As an endogenous agonist at the cannabinoid receptor CB1 and the capsaicin-receptor TRPV1, anandamide may exert both anti- and pronociceptive actions. Therefore we studied the effects of anandamide and other activators of both receptors on changes in free cytosolic calcium ([Ca2+]i) in acutely dissociated small dorsal root ganglion neurons (diameter: ≤30 μm). Anandamide (10 μM) increased [Ca2+]iin 76% of the neurons. The EC50was 7.41 μM, the Hill slope was 2.15 ± 0.43 (mean ± SE). This increase was blocked by the competitive TRPV1-antagonist capsazepine (10 μM) and in Ca2+-free extracellular solution. Neither exclusion of voltage-gated sodium channels nor additional blockade of voltage-gate…

Hot TemperatureCannabinoid receptorPolyunsaturated AlkamidesPhysiologyTRPV1TRPV Cation ChannelsArachidonic AcidsPharmacologyCalcium in biologyRats Sprague-Dawleychemistry.chemical_compoundGanglia SpinalPhysical StimulationAnimalsDrug InteractionsDronabinolEgtazic AcidChelating AgentsNeuronsCalcium metabolismAnalysis of VarianceDose-Response Relationship DrugChemistryGeneral NeuroscienceExtracellular FluidAnandamideCalcium Channel BlockersEndocannabinoid systemRatsNociceptionCalciumCapsaicinEndogenous agonistEndocannabinoidsJournal of Neurophysiology
researchProduct

Reduction of clozapine-induced hypersalivation by pirenzepine is safe.

2004

Introduction Hypersalivation is known as a frequent, disturbing, and socially stigmatizing side effect of therapy with the atypical antipsychotic clozapine. It has been shown that the addition of the anticholinergic pirenzepine is able to reduce clozapine-induced hypersalivation, probably by blocking M4-receptors. Nevertheless, a pharmacokinetic interaction between both compounds cannot be excluded. Methods In this pilot study, 29 schizophrenic patients (ICD-10; 51.7 % female; age: 36.7 +/- 8.7 years [mean +/- SD]) were included. Serum concentrations of clozapine and its pharmacologically active metabolite N-desmethylclozapine were determined under steady-state conditions by automated HPLC …

HypersalivationAdultMalemedicine.medical_specialtySide effectmedicine.drug_classAtypical antipsychoticPilot ProjectsMuscarinic AntagonistsPharmacologyInternal medicinemedicineAnticholinergicHumansPharmacology (medical)Drug InteractionsClozapineClozapineActive metaboliteChromatography High Pressure LiquidCross-Over StudiesDose-Response Relationship DrugChemistryGeneral MedicinePirenzepineSialorrheaMiddle AgedPirenzepinePsychiatry and Mental healthDose–response relationshipEndocrinologySchizophreniaFemaleSpectrophotometry Ultravioletmedicine.symptommedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

Automated Determination of Paroxetine and Its Main Metabolite by Column Switching and On-Line High-Performance Liquid Chromatography

1994

An automated column-switching method coupled to isocratic high-performance liquid chromatography has been developed for simultaneous determination of blood levels of paroxetine and its nonconjugated main metabolite BRL 36610. The lower limits of detection were 9-15 nmol/L (3-5 ng/ml) and linearity between drug concentration and detector response was found for 0-1,500 nmol/L (0-500 ng/ml). The method could be applied to the analysis of serum samples obtained from depressed patients who were treated with daily oral doses of 20 or 40 mg of paroxetine. After the 20-mg dose, the mean blood level of paroxetine was 69 nM (23 ng/ml), whereas the metabolite BRL 36610 was detectable in only one of 5 …

ImipramineMetaboliteSensitivity and SpecificityHigh-performance liquid chromatographyImipramineMixed Function Oxygenaseschemistry.chemical_compoundCytochrome P-450 Enzyme SystemPiperidinesOral administrationDesipraminemedicineHumansDrug InteractionsPharmacology (medical)Chromatography High Pressure LiquidPharmacologyDetection limitChromatographyParoxetineParoxetineCytochrome P-450 CYP2D6chemistryFemaleQuantitative analysis (chemistry)medicine.drugTherapeutic Drug Monitoring
researchProduct

Fluvastatin stabilizes the blood–brain barrier in vitro by nitric oxide-dependent dephosphorylation of myosin light chains

2006

Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme-A reductase and the downstream mevalonate pathway is in part responsible for the beneficial effects that statins exert on the cardiovascular system. In this study we aimed at analysing the stabilizing effects of fluvastatin on the blood-brain barrier (BBB) integrity, using an in vitro co-culture model of ECV304 and C6, or primary bovine endothelial cells and rat astrocytes. Fluvastatin dose-dependently (1-25 micromol/l) increased barrier integrity as analysed by measurements of transendothelial electrical resistance (TEER). This effect (117.4+/-2.6% at 25 micromol/l) was significantly reduced by the nitric oxide (NO) synthase inhibitor L…

IndolesMyosin Light ChainsMyosin light-chain kinaseGeranylgeranyl pyrophosphatePhosphataseFarnesyl pyrophosphateBiologyNitric OxideBlood–brain barrierAntioxidantsCapillary PermeabilityFatty Acids MonounsaturatedDephosphorylationMiceCellular and Molecular Neurosciencechemistry.chemical_compoundElectric ImpedancemedicineAnimalsDrug InteractionsEnzyme InhibitorsFluvastatinCells CulturedPharmacologyAnalysis of VarianceMicroscopy Confocalomega-N-MethylarginineDose-Response Relationship DrugEndothelial CellsBiological TransportMolecular biologyCoculture TechniquesRatsmedicine.anatomical_structurechemistryBiochemistryBlood-Brain BarrierAstrocytesModels AnimalCattleMevalonate pathwayFluvastatinmedicine.drugNeuropharmacology
researchProduct

Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury

2005

Inflammation plays a major pathological role in spinal cord injury (SCI). Although antiinflammatory treatment using the glucocorticoid methyprednisolone sodium succinate (MPSS) improved outcomes in several multicenter clinical trials, additional clinical experience suggests that MPSS is only modestly beneficial in SCI and poses a risk for serious complications. Recent work has shown that erythropoietin (EPO) moderates CNS tissue injury, in part by reducing inflammation, limiting neuronal apoptosis, and restoring vascular autoregulation. We determined whether EPO and MPSS act synergistically in SCI. Using a rat model of contusive SCI, we compared the effects of EPO [500-5,000 units/kg of bod…

InflammationPharmacologyProinflammatory cytokineRats Sprague-DawleymedicineAnimalsDrug InteractionsMethylprednisolone HemisuccinateInterleukin 6ErythropoietinSpinal cord injurySpinal Cord InjuriesMultidisciplinarybiologyInterleukin-6Tumor Necrosis Factor-alphabusiness.industryBiological Sciencesmedicine.diseaseRecombinant ProteinsRatscytokines glucocorticoids inflammation neuroprotection traumaMethylprednisoloneErythropoietinImmunologybiology.proteinTumor necrosis factor alphamedicine.symptombusinessGlucocorticoidmedicine.drugProceedings of the National Academy of Sciences
researchProduct

Effect of diazoxide on left ventricular performance in hypertension.

1975

The effect of diazoxide on left ventricular performance during rest and isometric exercise (handgrip) was examined in 16 unselected hypertensive patients, 6 of whom had been pretreated with the beta-adrenergic blocking agent pindolol. Diazoxide regularly and promptly produced a fall in left ventricular systolic and end diastolic pressures, and an increase in heart rate and left ventricular dp/dtmax. Haemodynamic changes were maximal 2 minutes after injection of the drug and decreased little over the next 8 minutes. After beta-adrenergic blockade, diazoxide caused a more pronounced reduction in left ventricular systolic pressure and a less marked fall in end-diastolic pressure, whilst the di…

InotropeAdultMalemedicine.medical_specialtyPhysical ExertionDiastoleHemodynamicsBlood PressureIsometric exerciseHeart RateInternal medicineHeart rateDiazoxideMedicineHumansPharmacology (medical)Drug InteractionsPharmacologybusiness.industryDiazoxideHemodynamicsGeneral MedicineMiddle AgedMyocardial ContractionBlood pressureAnesthesiaPindololHypertensionInjections Intravenouscardiovascular systemVentricular pressureCardiologyFemalebusinessmedicine.drugEuropean journal of clinical pharmacology
researchProduct

The positive inotropic effect of phenylephrine in the presence of propranolol. Increase in time to peak force and in relaxation time without increase…

1978

The effects of phenylephrine on the shape of the contraction curve and on the cyclic adenosine 3',5'-monophosphate (c-AMP) content were studied in electrically driven (frequency 0.2 Hz) cat papillary muscles. All experiments were done in the presence of 1 micron propranolol in order to minimize interference from beta-adrenoceptors. 1. Phenylephrine increased the force of contraction in a concentration-dependent manner. Maximal effects (about 200% of control) occurred at 30 micron phenylephrine. 2. The positive inotropic effect (PIE) of phenylephrine was antagonized by phentolamine. Phentolamine, 5 micron, produced a parallel shift of the concentration-response curve for the PIE of phenyleph…

Inotropemedicine.medical_specialtyContraction (grammar)Time FactorsPharmacology toxicologyAdrenergic beta-AntagonistsPropranololIn Vitro TechniquesPhenylephrineHeart RateInternal medicinemedicineCyclic AMPAnimalsDrug InteractionsPhentolaminePhenylephrinePharmacologyChemistryMyocardiumGeneral MedicineAdenosineMyocardial ContractionPropranololC++ AMPStimulation ChemicalEndocrinologyCatsTime to peakmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct